相似文献
1
Aiming for spatial and temporal control of gene expression.
Elife. 2025 Jul 10;14:e107945. doi: 10.7554/eLife.107945.
2
Identification of relevant analytical methods for adeno-associated virus stability assessment during formulation development.
Microbiol Spectr. 2025 Jun 30:e0180624. doi: 10.1128/spectrum.01806-24.
3
Activated alpha 9 integrin expression enables sensory pathway reconstruction after spinal cord injury.
Acta Neuropathol Commun. 2025 May 2;13(1):89. doi: 10.1186/s40478-025-01995-0.
4
Non-invasive detection of adeno-associated viral gene transfer using a genetically encoded CEST-MRI reporter gene in the murine heart.
Sci Rep. 2018 Mar 15;8(1):4638. doi: 10.1038/s41598-018-22993-4.
5
The drug-elicitable alternative splicing module for tunable vector expression in the heart.
Nat Cardiovasc Res. 2025 Jun 13. doi: 10.1038/s44161-025-00665-7.
6
Investigation of dose-exposure-response relationship for adeno-associated virus-mediated delivery of antibody genes.
J Pharmacol Exp Ther. 2025 Jun;392(6):103601. doi: 10.1016/j.jpet.2025.103601. Epub 2025 May 7.
7
Novel Immune Response Evasion Strategy to Redose Adeno-associated Viral Vectors and Prolong Survival in Surfactant Protein-B Deficient Mice.
Am J Respir Cell Mol Biol. 2025 Jan 13. doi: 10.1165/rcmb.2024-0247OC.
8
Cardiac-Targeted AAV5-S100A1 Gene Therapy Protects Against Adverse Remodeling and Contractile Dysfunction in Postischemic Hearts.
Circ Heart Fail. 2025 Jul;18(7):e012479. doi: 10.1161/CIRCHEARTFAILURE.124.012479. Epub 2025 Jun 19.
9
Combined sustained and triggered release for sequential viral-transduction from collagen-based scaffolds for tissue regeneration.
Biomater Sci. 2025 Aug 5;13(16):4437-4446. doi: 10.1039/d5bm00623f.
10
Immunogenicity risk assessment of empty capsids present in adeno-associated viral vectors using predictive innate immune responses.
J Pharm Sci. 2024 Dec;113(12):3457-3469. doi: 10.1016/j.xphs.2024.09.006. Epub 2024 Sep 24.
本文引用的文献
1
Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery.
Nat Protoc. 2023 Nov;18(11):3413-3459. doi: 10.1038/s41596-023-00875-y. Epub 2023 Sep 21.
2
An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair.
Cell Stem Cell. 2023 Jan 5;30(1):96-111.e6. doi: 10.1016/j.stem.2022.11.012. Epub 2022 Dec 13.
3
Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing.
Nat Commun. 2022 Oct 10;13(1):5947. doi: 10.1038/s41467-022-33745-4.
4
The clinical landscape for AAV gene therapies.
Nat Rev Drug Discov. 2021 Mar;20(3):173-174. doi: 10.1038/d41573-021-00017-7.
5
Adeno-associated virus vector as a platform for gene therapy delivery.
Nat Rev Drug Discov. 2019 May;18(5):358-378. doi: 10.1038/s41573-019-0012-9.
6
Resolving Heart Regeneration by Replacement Histone Profiling.
Dev Cell. 2017 Feb 27;40(4):392-404.e5. doi: 10.1016/j.devcel.2017.01.013.
7
Modulation of tissue repair by regeneration enhancer elements.
Nature. 2016 Apr 14;532(7598):201-6. doi: 10.1038/nature17644. Epub 2016 Apr 6.
8
Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling.
J Gene Med. 2012 Sep-Oct;14(9-10):609-20. doi: 10.1002/jgm.2673.
9
Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution.
Gene Ther. 2011 Jan;18(1):43-52. doi: 10.1038/gt.2010.105. Epub 2010 Aug 12.
Zotero 插件